JP2023551559A5 - - Google Patents
Info
- Publication number
- JP2023551559A5 JP2023551559A5 JP2023533838A JP2023533838A JP2023551559A5 JP 2023551559 A5 JP2023551559 A5 JP 2023551559A5 JP 2023533838 A JP2023533838 A JP 2023533838A JP 2023533838 A JP2023533838 A JP 2023533838A JP 2023551559 A5 JP2023551559 A5 JP 2023551559A5
- Authority
- JP
- Japan
- Prior art keywords
- combination
- aforementioned
- antibody
- day cycle
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20211862 | 2020-12-04 | ||
| EP20211862.6 | 2020-12-04 | ||
| EP21158806 | 2021-02-23 | ||
| EP21158806.6 | 2021-02-23 | ||
| EP21163696.4 | 2021-03-19 | ||
| EP21163696 | 2021-03-19 | ||
| EP21172671.6 | 2021-05-07 | ||
| EP21172671 | 2021-05-07 | ||
| EP21177336 | 2021-06-02 | ||
| EP21177336.1 | 2021-06-02 | ||
| EP21205447 | 2021-10-29 | ||
| EP21205447.2 | 2021-10-29 | ||
| PCT/EP2021/084133 WO2022117799A2 (en) | 2020-12-04 | 2021-12-03 | Anti-cd19 combination therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026073819A Division JP2026133433A (ja) | 2020-12-04 | 2026-04-27 | 抗cd19併用療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023551559A JP2023551559A (ja) | 2023-12-08 |
| JP2023551559A5 true JP2023551559A5 (cg-RX-API-DMAC7.html) | 2024-12-11 |
Family
ID=78821967
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023533838A Pending JP2023551559A (ja) | 2020-12-04 | 2021-12-03 | 抗cd19併用療法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220184208A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4255480A2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023551559A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230131464A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021391623A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023010885A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3204063A1 (cg-RX-API-DMAC7.html) |
| CL (2) | CL2023001581A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL303384A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023006538A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202237184A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022117799A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016311136B2 (en) | 2015-08-21 | 2022-02-17 | Incyte Corporation | Combinations and uses thereof |
| ES2981046T3 (es) | 2016-05-30 | 2024-10-07 | Incyte Corp | Métodos para predecir el beneficio terapéutico de una terapia anti-CD19 en pacientes |
| SMT202100317T1 (it) | 2016-06-27 | 2021-07-12 | Morphosys Ag | Formulazioni di anticorpi anti-cd19 |
| WO2018078123A1 (en) | 2016-10-28 | 2018-05-03 | Morphosys Ag | Combination of anti cd19 antibody with a bcl-2 inhibitor and uses thereof |
| KR20200030337A (ko) | 2018-09-12 | 2020-03-20 | 주식회사 녹십자랩셀 | 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물 |
| WO2021084062A1 (en) * | 2019-10-31 | 2021-05-06 | Morphosys Ag | Anti-cd19 therapy in combination with lenalidomide for the treatment of leukemia or lymphoma |
| US20230357392A1 (en) * | 2021-12-22 | 2023-11-09 | Morphosys Ag | Treatment Paradigm for an Anti-CD19 Antibody Therapy |
| AU2023285109A1 (en) * | 2022-06-10 | 2024-12-12 | Incyte Corporation | Combination therapy comprising sirp alpha fusion protein and anti-cd19 antibody for treatment of cancer |
| WO2023245106A1 (en) | 2022-06-16 | 2023-12-21 | Abbvie Biotherapeutics Inc. | Anti-cd19 antibody drug conjugates |
| WO2024037594A1 (en) * | 2022-08-19 | 2024-02-22 | Beijing Innocare Pharma Tech Co., Ltd. | Combination treatment with orelabrutinib and tafasitamab |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| JP3614866B2 (ja) | 1997-06-12 | 2005-01-26 | リサーチ コーポレイション テクノロジーズ,インコーポレイティド | 人工抗体ポリペプチド |
| JP4733635B2 (ja) | 2003-07-31 | 2011-07-27 | イミューノメディクス、インコーポレイテッド | 抗cd19抗体 |
| US7902338B2 (en) | 2003-07-31 | 2011-03-08 | Immunomedics, Inc. | Anti-CD19 antibodies |
| WO2007002223A2 (en) | 2005-06-20 | 2007-01-04 | Medarex, Inc. | Cd19 antibodies and their uses |
| AU2006332155B2 (en) | 2005-12-30 | 2013-01-10 | Cancer Research Technology Limited | Anti-CD19 antibodies with reduced immunogenicity |
| RS53263B (sr) | 2006-08-14 | 2014-08-29 | Xencor Inc. | Optimizovana antitela usmerena na cd19 |
| US8323653B2 (en) | 2006-09-08 | 2012-12-04 | Medimmune, Llc | Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| CA2693053C (en) | 2007-05-30 | 2021-01-05 | Xencor, Inc. | Methods and compositions for inhibiting cd32b expressing cells |
| CN101903403B (zh) | 2007-10-19 | 2016-03-16 | 西雅图基因公司 | Cd19结合剂及其应用 |
| CA2753158A1 (en) | 2009-02-23 | 2010-08-26 | Glenmark Pharmaceuticals S.A. | Humanized antibodies that bind to cd19 and their uses |
| WO2011147834A1 (en) | 2010-05-26 | 2011-12-01 | Roche Glycart Ag | Antibodies against cd19 and uses thereof |
| EP2409993A1 (en) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anti-CD19 antibody having ADCC function with improved glycosylation profile |
| EP2409712A1 (en) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile |
| EP3018145B1 (en) * | 2010-10-27 | 2018-04-04 | Amgen Research (Munich) GmbH | Means and methods for treating dlbcl |
| EP2524929A1 (en) | 2011-05-17 | 2012-11-21 | Sanofi | Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms |
| ES2981046T3 (es) * | 2016-05-30 | 2024-10-07 | Incyte Corp | Métodos para predecir el beneficio terapéutico de una terapia anti-CD19 en pacientes |
| EP3487525A4 (en) * | 2016-07-22 | 2020-03-18 | Seattle Genetics, Inc. | COMBINATION THERAPY WITH CD19-ADC AND RCHP |
| CN114206346A (zh) * | 2019-05-03 | 2022-03-18 | 凯德药业股份有限公司 | 施用嵌合抗原受体免疫疗法的方法 |
-
2021
- 2021-12-03 AU AU2021391623A patent/AU2021391623A1/en active Pending
- 2021-12-03 WO PCT/EP2021/084133 patent/WO2022117799A2/en not_active Ceased
- 2021-12-03 EP EP21819888.5A patent/EP4255480A2/en active Pending
- 2021-12-03 JP JP2023533838A patent/JP2023551559A/ja active Pending
- 2021-12-03 KR KR1020237022358A patent/KR20230131464A/ko active Pending
- 2021-12-03 IL IL303384A patent/IL303384A/en unknown
- 2021-12-03 BR BR112023010885A patent/BR112023010885A2/pt unknown
- 2021-12-03 TW TW110145312A patent/TW202237184A/zh unknown
- 2021-12-03 US US17/541,627 patent/US20220184208A1/en active Pending
- 2021-12-03 MX MX2023006538A patent/MX2023006538A/es unknown
- 2021-12-03 CA CA3204063A patent/CA3204063A1/en active Pending
-
2023
- 2023-06-01 CL CL2023001581A patent/CL2023001581A1/es unknown
-
2026
- 2026-02-03 CL CL2026000320A patent/CL2026000320A1/es unknown